2 results
Approved WMOPending
The primary objective is to assess if there are any differences in terms of Bone Mineral Density between patients receiving the BICON-PLUS NT with an alumina reduced device surface (study group) and a group of patients receiving the BICON-PLUS with…
Approved WMOCompleted
The primary objective of this phase III study is to demonstrate that lixisenatide can reduce cardiovascularmorbidity and mortality (composite endpoint of cardiovascular (CV) death, non-fatal myocardialinfarction (MI), non-fatal stroke,…